Introduction {#Sec1}
============

Brain-derived neurotrophic factor (BDNF) modulates hippocampal plasticity, hippocampal-dependent memory and has been suggested to be involved in the pathophysiology of different mental disorders \[[@CR10], [@CR17], [@CR43]\]. In particular, a close relationship appears to exist between BDNF and schizophrenia \[[@CR27]\] and affective disorders \[[@CR40]\], implicating that BDNF may be a candidate gene for these mental disorders. BDNF acts as a vital trophic protein for neuronal survival and differentiation in the developing nervous system \[[@CR22]\] and modulates cholinergic, dopaminergic, and serotonergic neurons, which may also have an impact on the etiopathogenesis of mental disorders \[[@CR13], [@CR38], [@CR41]\]. Recent studies revealed an important role of BDNF in the regulation of glutamatergic synapses and glutamate receptor activity \[[@CR6]\], which may represent one important link between BDNF and hippocampal function. Glutamate receptor function is essential for memory functions, and the hippocampal pyramidal layers are densely packed with glutamate-containing excitatory neurons. These neurons are involved in the induction of long-term potentiation (LTP) and long-term depression (LTD), which are the cellular and molecular mechanisms underlying memory \[[@CR29], [@CR42]\].

The gene encoding human BDNF is localized to chromosome 11, band p13 and it encodes a precursor peptide (proBDNF), which is cleaved to form the mature protein via proteolyses \[[@CR10], [@CR28]\]. It was shown that the frequent nonconservative amino acid substitution valine to methionine on codon 66 (val66met---polymorphism, dbSNP number rs6265) in the 5′ signal domain of BDNF gene leads to disturbances in the intracellular packaging and regulated secretion of BDNF without affecting mature BDNF protein function \[[@CR10]\]. In normal individuals, this frequent polymorphism (met-allele carriers) has been shown to affect human hippocampal function, episodic memory, and declarative memory \[[@CR7], [@CR10], [@CR17], [@CR19]\]. In particular, previous studies revealed smaller hippocampal volume in met-allele carriers independent of age and gender in healthy subjects \[[@CR5], [@CR37]\]. Studies using magnetic resonance spectroscopic imaging (MRS) reported an association between the functional BDNF val66met polymorphism and reduced hippocampal N-acetyl aspartate (NAA) \[[@CR10], [@CR41]\].

The aims of the present study were, first, to replicate and extend prior findings of BDNF effects on hippocampal volume \[[@CR5], [@CR37]\] and NAA \[[@CR10], [@CR41]\] by assessing the effect of the BDNF val66met polymorphism in a large and ethnically homogeneous sample including healthy individuals and psychiatric patients suffering from psychotic disorders (schizophrenia and bipolar affective disorder, heterogeneous clinical status). Second, we sought to provide empirical evidence for the hypothesis that the BDNF val66met polymorphism may also impact on glutamatergic mechanisms in the human hippocampus \[[@CR6], [@CR41]\]. For these purposes, we determined hippocampal brain volumes using structural magnetic resonance imaging (MRI) and performed in vivo measures of hippocampal NAA, choline, creatine, and glutamate/glutamine using proton magnetic resonance spectroscopy (^1^H-MRS). Furthermore, in order to address memory indices of hippocampal function, subjects were tested with the verbal learning memory test (VLMT, \[[@CR35]\]). Based on the results of prior studies, we hypothesized that carriers of the met-allele (val/met, met/met genotype) would reveal lower N-acetyl aspartate and glutamate levels, lower hippocampal gray matter volume, and worse memory performance in the VLMT than val/val homozygotes.

Materials and methods {#Sec2}
=====================

Subjects {#Sec3}
--------

Sixty-six patients suffering from schizophrenia (SZ), 45 patients with bipolar I disorder (BP), and 47 healthy controls participated in the study. All subjects were recruited from the Saarland area, and all of them were Caucasians of European ancestry (most German). A subsample of these subjects underwent MRI (*n* = 105) or MRS (*n* = 103) scanning. All patients provided informed consent before entering the study, and the study design was approved by the local ethics committee. Diagnoses were based on the German version of the Structural Clinical Interview for DSM IV \[[@CR44]\] and were consented within members of the study group and the treating clinical psychiatrist, who was blind to the aims of the study. Patients were excluded from the study if they met any of the following criteria: organic central nervous system disorder (e.g., epilepsy, traumatic brain injury, infectious, toxic, or cerebrovascular disease), mental retardation, or inadequate knowledge of the German language. At the time of the study, most patients received, depending on the disease, a stable medication, including typical and atypical neuroleptics, mood stabilizers, and benzodiazepines. Healthy control subjects exhibited no past or present psychiatric, neurological or medical disorder and had no positive family history of psychiatric disorders. Demographic data for the study sample are given in Table [1](#Tab1){ref-type="table"}. Clinical characteristics and psychopathological scores for the patient groups are presented in Table [2](#Tab2){ref-type="table"}.Table 1Demographic and clinical data of study subjectsVariableVal/valVal/metMet/metStatistic*P*All subjects *N*94568 Gender39 M, 55 F36 M, 20 F6 M, 2 Fχ²(2) = 9.20.01 Age (years; ± SD)37.6 ± 11.738.8 ± 13.339.5 ± 14.7F(2, 155) = 0.20.81 Education (years; ± SD)13.7 ± 3.013.6 ± 2.914.0 ± 3.5F(2, 155) = 0.10.95 Diagnosis: control subjects (*N*)27164χ²(4) = 3.20.52 Diagnosis: schizophrenia (*N*)43212 Diagnosis: bipolar disorder (*N*)24192Subjects with hippocampal MRI data *N*60414 Gender26 M, 34 F28 M, 13 F2 M, 2 Fχ²(2) = 6.10.047 Age (yrs; ± SD)38.03 ± 12.137.82 ± 13.848.53 ± 13.0F(2, 102) = 1.30.28 Education (years; ± SD)13.84 ± 2.9713.78 ± 2.815.25 ± 3.2F(2, 102) = 0.50.62 Diagnosis: control subjects (*N*)24123χ²(4) = 5.480.24 Diagnosis: schizophrenia (*N*)20120 Diagnosis: bipolar disorder (*N*)16171Subjects with hippocampal MRS data *N*61384 Gender28 M, 33 F28 M, 10 F2 M, 2 Fχ²(2) = 7.40.025 Age (years; ± SD)38.22 ± 12.337.48 ± 13.648.53 ± 13.1F(2, 100) = 1.350.26 Education (years; ± SD)13.74 ± 2.8613.97 ± 2.7115.25 ± 3.2F(2, 100) = 0.570.57 Diagnosis: control subjects (*N*)23113χ²(4) = 4.620.33 Diagnosis: schizophrenia (*N*)22130 Diagnosis: bipolar disorder (*N*)16141Data are presented as mean ± standard deviation unless otherwise indicated. Values are expressed as χ² statistics for categorical variables and *F* statistics for continuous variables. *conv*. conventional, *F* female, *N* number, *M* male, and *SD* standard deviationTable 2Clinical data and symptom ratings of the patient groups: data are presented as mean ± standard deviation unless otherwise indicatedVal/valVal/metMet/metStatistics*N*MeanSD*N*MeanSD*N*MeanSD*dfFP*Schizophrenia patients (MRS) CPZ (daily dosage)20398.0387.912204.2143.71, 302.740.11 CPZ (cumulative)2011,24118,767123,6383,2161, 301.910.18 Duration of psychosis (weeks)2045621246391, 300.000.98 PANSS positive2021.55.51222.06.21, 300.070.79 PANSS negative2023.26.61219.87.31, 301.740.20 PANSS general2049.28.81243.18.81, 303.620.067 PANSS total2093.815.61284.917.61, 302.220.15 MADRS total score1920.16.21115.55.11, 284.310.047Bipolar patients (MRS) Disease duration (years)1613.310.11513.912.0137.02, 292.170.13 MADRS total score154.13.4154.63.112.02, 280.330.72 YMRS142.33.1153.22.710.02, 270.810.46 Psychotic symptoms (no/yes)11/512/31/020.870.65 Neuroleptics (none/FG/SG)9/1/67/2/61/0/041.470.83 Lithium (no/yes)10/610/50/121.780.41 Other mood stabilizer (no/yes)4/124/110/120.360.84 Benzodiazepine (no/yes)12/3/113/2/01/0/041.480.83 Antidepressants (no/yes)13/38/71/023.280.19Values are expressed as χ² statistics for categorical variables and *F* statistics for continuous variables. *N* group size, *SD* standard deviation, *df* degrees of freedom, *FF* statistic, *P* error probability of first kind, *CPZ* chlorpromazine equivalent dose, *PANSS* positive and negative syndrome scale, *MADRS* Montgomery-Asberg depression rating scale, *YMRS* young mania rating scale, *FG* first-generation antipsychotic drugs, and *SG* second-generation antipsychotic drugs

MRI acquisition and volumetric measurement {#Sec4}
------------------------------------------

MRI scanning was performed on a 1.5-Tesla Magnetom Sonata (Siemens, Erlangen). A *T*1-weighted, magnetization prepared rapid gradient echo sequence (MPRAGE) (echo time, TE = 4 ms; repetition time, TR = 1.900 ms; inversion time, TI = 700 ms, flip angle = 15°, image matrix = 256 × 256 mm) generating 176 consecutive sagittal slices with a voxel size of 1 mm^3^ was acquired. Image processing and analysis used the software packages Analyze (Mayo Foundation, 1999), Statistical Parametric Mapping (SPM99, Institute of Neurology, London, UK, \[[@CR2]\], exclusively used in order to determine total gray matter volume) as well as interactive data language applications (IDL) generated in our imaging lab. First, the MR images were realigned in parallel to the AC--PC (anterior commissure and posterior commissure) plane. As described previously \[[@CR14]\], hippocampal morphometry in all participants was conducted manually by raters (hand tracing) who were blind to diagnosis and genotype. Hippocampal contours were drawn in the sagittal view using the "region of interest" tool implemented in the software Analyze. After having completed the drawing for all sagittal slices in which the hippocampus was visible, the correctness of the contours was controlled in the coronal and horizontal views. Subsequently, both the hippocampal volumes as marked by the two-dimensional drawings and the total brain volumes were determined using an automatic algorithm programmed in MATLAB and SPM99. Because we were interested in specific effects on the size of the hippocampus independent from total brain volumes, statistical analysis was performed on relative hippocampal volumes expressed by the quotient of hippocampal and total brain volume.

Proton magnetic resonance spectroscopy {#Sec5}
--------------------------------------

As described previously \[[@CR39]\], single-volume ^1^H-MRS was performed on a 1.5-Tesla Siemens Magnetom Sonata (Siemens, Erlangen) using a spin-echo sequence with water suppression and 128 scan averages (TE = 30, TR = 1.500). Regions of interest were defined in the left hippocampus, in the middle third of the left middle frontal gyrus (referred to as left dorsolateral prefrontal cortex), and in the left posterior frontomedian cortex along the cingulate sulcus. These regions were determined according to an exactly predefined and standardized algorithm with multiple rechecking procedures in a *T*2 gradient echo image (TrueFISP) with 24 slices each in three orthogonal orientations. The positions of the voxels were visually inspected and adjusted based on identifiable anatomical landmarks in reference to standard brain atlases. The voxel sizes were adjusted to the morphology of the anatomical target structures and were 10 × 35 × 10 mm^3^ for the hippocampus (see Fig. [1](#Fig1){ref-type="fig"}) and the middle third of the middle frontal gyrus, and 12 × 20 × 15 mm^3^ for the posterior frontomedian cortex.Fig. 1Magnetic resonance imaging (MRI) demonstrating the localization and well-adapted shape of the volume of interest (voxel size 10 × 35 × 10 mm^3^) placed in the *left* hippocampus (MR images in radiological convention) in **a** transversal, **b** coronal, and **c** sagittal orientation

All spectra were postprocessed by using the Siemens Medical Solutions spectroscopy software package on a Leonardo workstation. Following acquisition, low-frequency filtering for removal of the residual water signal and correction for frequency shifts were performed. Data were zero-filled from 1.024 to 2.048 points. After apodization of the time domain signal by a Hanning function with 700 ms width, the data were Fourier transformed to the frequency domain. The spectra were baseline corrected with a sixth-order polynomial and first-order phase-corrected. Curve fitting to the metabolic peaks was applied using Gaussian or Lorentzian line shapes at known frequencies. Relative metabolite concentrations for N-acetyl groups (NAA), choline-containing compounds (Cho), creatine and phosphocreatine (Cre), and glutamate plus glutamine (Glu + Gln) were determined, and the metabolic ratios NAA/Cre, NAA/Cho, Cho/Cre, and (Glu + Gln)/Cre were calculated. A model MRS spectrum from one subject is presented in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Typical proton magnetic resonance spectroscopy spectrum (1H-MRS) from the *left* hippocampus

VLMT {#Sec6}
----

Cognitive performance was measured using the German version of the Rey Auditory Verbal Learning Test (Verbal Learning Memory Test, VLMT, \[[@CR35]\]). The VLMT is a widely used neuropsychological test of verbal learning and memory with only minor requirement of language and motor skills. This test allows the assessment of verbal declarative memory and investigates the encoding capacity, the direct and delayed recall performance and episodic recognition abilities \[[@CR24]\].

Genotyping {#Sec7}
----------

DNA was extracted according to the salting out procedure \[[@CR32]\]. The following primers were used in the polymerase chain reaction (PCR): 5′-AAAGCCCTAACCAGTTTTCTG-3′ (forward) and 5′-TCCTCCAGCAGAAAGAGAAG-3′ (reverse). The PCR was done in a 50 μl reaction mixture containing 100 ng of genomic DNA, 200 μM of each dNTPs, 10 pmol of each primer, 0.5 units Taq-polymerase, and buffer (KCl 50 mM, Tris--HCl 10 mM, Tween 20 0.025%, BSA 0.025 mg/ml, and 2.0 mM MgCl2). The PCR reaction had an initial temperature of 94°C (5 min) followed by 35 cycles of denaturation (94°C, 45 s), annealing (58°C, 45 s), and extension (72°C, 45 s). An extension period of 7 min at 72°C followed the final cycle. The PCRs were done using an ABI GeneAmp^®^9700 cycler.

PCR products were digested at 37°C using Pml1 (NEB, Ipswich, MA, USA), separated on 2.0% agarose gels (ROTI^®^GAROSE NEEO, Roth, Karlsruhe), and genotyped according to the resulting fragment lengths. BDNF genotypes were called by two individuals being blind to the clinical data.

Statistics {#Sec8}
----------

For statistical analyses, SPSS for Windows 16.0 was used. Level of significance was set at α \< 0.05. All tests were two-tailed. Only in cases in which analyses were based on a priori hypotheses derived from literature (e.g., \[[@CR10], [@CR41]\]), results are presented without correction of error probabilities for multiple testing (see also \[[@CR41]\]).

In order to determine possible confounding variables, effects of age and duration of education on the dependent variables were assessed within the sample of healthy controls using Pearson product moment correlations, while one-way analysis of variance (ANOVA) was performed to examine the influence of the factors gender and handedness as well as (in the entire sample) of the factor diagnosis. For further analysis, the intervening variables education, age, gender, and diagnosis were included into the MANCOVA, as each of these intervening variables had a significant influence on some of the dependent variables.

Subjects of the three different groups (schizophrenia, bipolar I, and healthy controls) were separated according to the BDNF genotype into homozygous carriers of the val-allele (val/val) or the met-allele (met/met), and heterozygotes (val/met). These genotype groups were compared to each other with regard to the dependent variables (i) relative hippocampal volumes (left and right), (ii) MRS ratios in the left hippocampus, and (iii) overall performance in the verbal learning memory test. For (i) a repeated measures MANCOVA with between-subject factors BDNF genotype, gender and diagnosis, within-subject factor side and covariates age and education was calculated. For (ii) MANCOVA and for (iii) ANCOVA with factor BDNF genotype and the intervening variables education, age, gender, and diagnosis were performed. In case of significant effects for the factor BDNF genotype in the MANCOVA, we performed post-hoc comparisons between groups in order to further evaluate the genetic effect. In particular, to evaluate the effects of only one met-allele, val/met heterozygotes were compared with val homozygotes (val/val). In order to address the effect of two met-alleles, met homozygotes (met/met) were compared with val homozygotes (val/val).

To make our results more comparable to other studies, we calculated the effect sizes for the results of the ANOVA (*f* values).

Results {#Sec9}
=======

The frequency of the BDNF val/val genotype in the overall sample was 65% in schizophrenia patients and 54% in patients with bipolar I disorder, and 57% in healthy subjects, which is in accordance with previously published data. Overall, the genotype frequencies were in the Hardy--Weinberg equilibrium (*P* = 0.93).

BDNF effects on hippocampal volumes {#Sec10}
-----------------------------------

The inter-rater reliability (intraclass correlation coefficient = ICC) and the intra-rater reliability for the volumetric hippocampal measurement was 0.93 and 0.99, respectively. Repeated measures MANCOVA did not reveal any significant effect of the BDNF val66met polymorphism on relative hippocampal volume (*F*(2, 86) = 0.50, *P* = 0.61). Furthermore, MANCOVA did neither reveal a significant interaction side x BDNF nor diagnosis x BDNF.

BDNF effects on magnetic resonance spectroscopy markers in hippocampus, dorsolateral prefrontal, and frontomedian cortex {#Sec11}
------------------------------------------------------------------------------------------------------------------------

Initial MANCOVA (factor: BDNF, intervening variables education, age, gender, and diagnosis) showed a significant effect of BDNF val66met genotype on MRS ratios in the left hippocampus (*F*(10, 162) = 1.91, *P* = 0.048, effect size: *f* = 0.342), but not in the left dorsolateral prefrontal cortex (*F*(10, 176) = 0.91, *P* = 0.52) nor in the left posterior frontomedian cortex (*F*(10, 176) = 0.65, *P* = 0.77). For all the three regions, the interaction diagnosis x BDNF was not significant.

Post-hoc comparisons for BDNF genotype effects on MRS markers in the left hippocampus revealed that met/met homozygotes had significantly lower NAA/Cre (−21.1%; *F*(1, 52) = 4.80, *P* = 0.033, effect size: *f* = 0.303 and (Glu + Gln)/Cre (−46.0%; *F*(1, 52) = 6.20, *P* = 0.016, effect size: *f* = 0.346) ratios as compared with val/val homozygotes (Fig. [3](#Fig3){ref-type="fig"}a, b), while the difference in the NAA/Cho ratio did not reach the level of significance (−15.1%; *F*(1, 52) = 1.78, *P* = 0.185). Mean values of these MRS ratios in the heterozygous val/met group generally laid in between the two homozygous groups. However, no statistically significant effect for a reduction in the MRS ratios in the val/met group as compared with the val/val homozygotes could be observed.Fig. 3Significant effects of the functional BDNF val66met polymorphism rs6265 on magnetic resonance spectroscopic markers (**a** NAA/Cre; **b** (Glu + Gln)/Cre) in the *left* hippocampus. \**P* \< 0.05. The *y*-axis represents the ratios between NAA/Cre and (Glu + Gln)/Cre

When all met-allele carriers (homozygotes and heterozygotes) were pooled and contrasted with val/val homozygotes, no significant differences in MRS ratios could be detected. The interaction diagnosis × BDNF did not show a significant effect.

BDNF effects on verbal memory {#Sec12}
-----------------------------

Consistent with previous studies on verbal memory, carriers of the met-allele numerically revealed a reduced overall performance (sum of five direct recalls) in the verbal learning memory test, but this did not turn out to be statistically significant in the ANCOVA (*F*(2, 98) = 0.30, *P* = 0.74, effect size: *f* \< 0.1).

Discussion {#Sec13}
==========

In the present study, we investigated the impact of the functional BDNF val66met polymorphism on magnetic resonance spectroscopic markers (NAA/Cre, NAA/Cho, Cho/Cre, and (Glu + Gln)/Cre) in the left hippocampus, left dorsolateral prefrontal, and left posterior frontomedian cortex, as well as on hippocampal volumes and on verbal memory capacity in a group of 158 subjects (66 schizophrenia patients, 45 BD patients, and 47 healthy controls). Our main finding was a significant effect of BDNF genotype on metabolic markers specifically in the left hippocampus. In particular, homozygous carriers of the met-allele exhibited significantly lower NAA/Cre and (Glu + Gln)/Cre metabolic ratios as compared with val/val homozygotes (Fig. [3](#Fig3){ref-type="fig"}). This effect was confirmed by controlling for identified intervening covariates. Although in the heterozygous val/met group, the mean values of these MRS ratios laid in between the two homozygous groups, no significant effect of the presence of only one met-allele could be detected in this group. Thus, our data suggest that BDNF effects on NAA/Cre and (Glu + Gln)/Cre ratios in the left hippocampus may be specific for (or at least most pronounced in) homozygous carriers of the met-allele. Alternatively, these effects may be present in heterozygotes for the met-allele as well, but may be too small to have reached the level of statistical significance in our sample.

Overall, these MRS results are consistent with previous reports of a significant reduction in left hippocampal NAA/Cre and NAA/Cho levels in carriers of the BDNF rs6265 met-allele \[[@CR10], [@CR41]\]. Thus, we were able to replicate these prior findings in an ethnically homogeneous sample of only caucasians. Furthermore, our data that were acquired in a mixed sample of both healthy subjects and psychiatric patients with psychotic disorders suggest that the observed BDNF genotype effects on MRS markers may be relatively independent of these psychiatric diagnoses as there were no effects of diagnosis on these markers and no genotype x diagnosis interactions. Moreover, our findings provide in vivo evidence for an effect of the functional BDNF polymorphism on glutamate levels in the left human hippocampus, which is consistent with the theory that BDNF may impact NAA via its influence on the glutamate system \[[@CR6], [@CR41]\].

Our negative MRS finding in the posterior frontomedian cortex seems to contradict the very recent observation of higher NAA levels in the anterior cingulate cortex of met-allele carriers \[[@CR13]\]. The authors interpreted this finding tentatively as an up-regulation of cingulate NAA to compensate decreasing hippocampal NAA in met-allele carriers. Several methodological differences may account for these partially discrepant results, such as the precise placement and the size of MRS voxels, the measurement of absolute versus relative metabolite concentrations and numerical as well as genetic differences between samples. For example, it is unclear whether and to what extent the rather large ACC voxel recorded by Gallinat and colleagues overlaps with our voxel in the posterior frontomedian cortex, which was anatomically precisely defined as (and adjusted to) the (left sided) cingulate cortex located dorsally and posterior to the genu of the corpus callosum along the cingulate sulcus (see \[[@CR23]\], for a very similar voxel positioning, however, centered on the interhemispheric fissure). Functionally, this cortical region has been implicated in adaptive cognitive control of behavior, in particular in background monitoring of the environment for potentially significant sensory events \[[@CR15]\]. Given the fact that BDNF effects on MRS markers appear to be regionally specific (as indicated by the present and other results), this highlights the importance of investigating clearly defined and (presumably) functionally homogeneous brain regions.

With regard to BDNF effects on brain structure, we were unable to replicate prior findings of a hippocampal volume reduction in carriers of the met-allele \[[@CR12], [@CR21], [@CR37]\] as we did not find any effect of BDNF genotype on hippocampal volume. Thus, this negative finding is more consistent with other recent studies which also did not observe BDNF genotype effects on structural volumes of the hippocampus \[[@CR33], [@CR41]\]. While our finding further excludes that the observed BDNF effects on MRS markers might have resulted from confounding differences in hippocampus volume (see \[[@CR41]\]), it is still possible that BDNF may also impact on hippocampal structure, but with lower effect size, which may not be observable in diagnostically heterogeneous samples. Furthermore, the results are compatible with the suggestion that neurochemical MRS markers may be more sensitive to BDNF genotype effects than volumetric measures \[[@CR41]\]. Interestingly, one study showed that the BDNF val66met polymorphism is associated with temporal gray matter loss over 4 years in patients with Bipolar I Disorder \[[@CR31]\]. Hence, it is possible that BDNF effects on brain structure may only be observable in longitudinal studies that assess changes in the course of brain disorders. However, in this context, it is worth to mention that schizophrenia and bipolar affective disorder share in parts a common pathophysiological pathway and display similar symptoms, but differ in the disease course and in the cortical gray matter loss \[[@CR9], [@CR34]\].

Finally, our finding of a numerical, but nonsignificant effect of BDNF genotype on verbal memory is quite consistent with previous reports of BDNF genotype effects on episodic memory and, to a lesser extent, on verbal memory \[[@CR5], [@CR10], [@CR16]\]. As verbal memory tests like the California Verbal Learning Test (CVLT) and the Verbal Learning Memory Test (VLMT) may (in comparison to episodic memory tests) also impose considerable demands on prefrontal cortical functions, this may explain the lack of statistical significance for BDNF effects on the VLMT in the present study (for a similar discussion see Egan et al. 2003). Given the fact that BDNF is well-known to facilitate LTP, i.e., memory-related processes in the hippocampus \[[@CR1], [@CR5], [@CR8], [@CR10], [@CR12], [@CR21], [@CR22], [@CR36]--[@CR38]\], further studies are definitely required to clarify possible effects of BDNF genotype on hippocampus-dependent cognition. A possible bias of these results might be the effects of concomitant medication on cerebral neurochemistry. This phenomenon is being controversially disputed by different authors, and there might be an effect of neuroleptics on cerebral NAA levels \[[@CR4], [@CR11], [@CR18]\], although in the light of other studies, this appears to be unlikely \[[@CR18], [@CR26]\].

It can further be speculated whether our results are linked to the heritability of our outcome measures. Different studies point toward heritability of hippocampal volumetric measures, hippocampal spectroscopy parameters, and of verbal memory \[[@CR20], [@CR25], [@CR30]\]. Our finding of a BDNF effect in a mixed sample of healthy controls and patients suffering from schizophrenia and BP is indeed compatible with the assumption of heritability of our outcome parameters.

In summary, the present findings provide further evidence for a crucial role of BDNF in hippocampal functioning. In this context, BDNF has been linked to hippocampus-related forms of learning and memory, in particular via its effects on activity-dependent changes in synaptic strength of glutamatergic synapses \[[@CR3]\]. BDNF has been shown both to facilitate glutamate release at the presynapse and to increase postsynaptic glutamate receptor phosphorylation and synthesis \[[@CR6]\]. In consideration of these findings, only recently, it had been hypothesized that BDNF may exert its observed effects on NAA via its influence on the glutamatergic system \[[@CR41]\]. Consistent with this hypothesis, the present results provide first in vivo evidence for an effect of the functional BDNF val66met polymorphism on the glutamate system in human hippocampus. Furthermore, our data suggest that these BDNF effects on NAA and glutamate in the hippocampus may be most pronounced in homozygous carriers of the BDNF met-allele.
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